2024 Molecular Pathology and Technical EQA scheme registration closes in:

Molecular testing in Lung Cancer

  • Scheme code
  • Target
    Mutations in the EGFR, KRAS and BRAF genes.
  • Sample material

    Mix of real tissue and artificial paraffin embedded (FFPE) materials designed to simulate a real patient sample. NOTE: Samples provided as cut sections (rolled scrolls) ONLY – we cannot provide slide mounted materials.

  • Scheme format

    Assessment of genotyping, and biological and clinical interpretation. For cases 1 and 2, participants are expected to return a clinical report which includes a complete interpretation of the results. The remaining 8 cases require genotyping-only.

    The minimum requirement is EGFR. If you provide a clinical service for BRAF (p.V600E only) gene testing or KRAS genes, these should be included in the interpretation of results. The testing of other genes is optional. Only variants that have been validated in the test samples will be assessed.

    For EGFR testing, labs should expect mutations in all 4 Tyrosine Kinase (TK) domain exons (for example, but not exclusively p.Gly719Ser, p.Thr790Met, deletions in exon 19, and p.Leu858Arg).

    Open to laboratories from ALL countries.

  • Reporting Language

    Reports accepted in English ONLY.

  • Additional information

    Mutation allelic frequencies have been validated using ddPCR.

    We would like to thank AstraZeneca for the educational grant to deliver this EQA. Consequently, the cost of this scheme has been discounted (from £438) and shows as £0.00 when users purchase it via their EMQN website account.

  • Performance criteria
    Performance Criteria DO Apply
  • Accreditation
    This scheme IS covered by the scope of EMQN's accreditation
  • Collaborator
    There are no collaborators
Translate »